Literature DB >> 16165082

Characterization of a putative fusogenic sequence in the E2 hepatitis G virus protein.

Cristina Larios1, Jordi Casas, María A Alsina, Concepción Mestres, María J Gómara, Isabel Haro.   

Abstract

With the aim of better understanding the fusion process mediated by the envelope proteins of the hepatitis G virus (HGV/GBV-C), we have investigated the interaction with model membranes of two overlapping peptides [(267-284) and (279-298)] belonging to the E2 structural protein. The peptides were compared for their ability to perturb lipid bilayers by means of different techniques such as differential scanning calorimetry and fluorescence spectroscopy. Furthermore, the conformational behaviour of the peptides in different membrane environments was studied by Fourier-transform infrared spectroscopy and circular dichroism. The results showed that only the E2(279-298) peptide sequence was able to bind with high affinity to negatively charged membranes, to permeabilize efficiently negative lipid bilayers, to induce haemolysis, and to promote inter-vesicle fusion. This fusogenic activity could be related to the induced peptide conformation upon interaction with the target membrane.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16165082     DOI: 10.1016/j.abb.2005.06.027

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  9 in total

1.  Characterization of a peptide domain within the GB virus C envelope glycoprotein (E2) that inhibits HIV replication.

Authors:  Jinhua Xiang; James H McLinden; Thomas M Kaufman; Emma L Mohr; Nirjal Bhattarai; Qing Chang; Jack T Stapleton
Journal:  Virology       Date:  2012-05-16       Impact factor: 3.616

2.  Characterization of an immunodominant antigenic site on GB virus C glycoprotein E2 that is involved in cell binding.

Authors:  James H McLinden; Thomas M Kaufman; Jinhua Xiang; Qing Chang; Donna Klinzman; Alfred M Engel; Georg Hess; Urban Schmidt; Michael Houghton; Jack T Stapleton
Journal:  J Virol       Date:  2006-10-11       Impact factor: 5.103

3.  Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.

Authors:  Yvonne Koedel; Kristin Eissmann; Holger Wend; Bernhard Fleckenstein; Heide Reil
Journal:  J Virol       Date:  2011-05-04       Impact factor: 5.103

4.  GB virus type C envelope protein E2 elicits antibodies that react with a cellular antigen on HIV-1 particles and neutralize diverse HIV-1 isolates.

Authors:  Emma L Mohr; Jinhua Xiang; James H McLinden; Thomas M Kaufman; Qing Chang; David C Montefiori; Donna Klinzman; Jack T Stapleton
Journal:  J Immunol       Date:  2010-09-08       Impact factor: 5.422

5.  Chimpanzee GB virus C and GB virus A E2 envelope glycoproteins contain a peptide motif that inhibits human immunodeficiency virus type 1 replication in human CD4⁺ T-cells.

Authors:  James H McLinden; Jack T Stapleton; Donna Klinzman; Krishna K Murthy; Qing Chang; Thomas M Kaufman; Nirjal Bhattarai; Jinhua Xiang
Journal:  J Gen Virol       Date:  2013-01-03       Impact factor: 3.891

Review 6.  GB virus type C interactions with HIV: the role of envelope glycoproteins.

Authors:  Emma L Mohr; Jack T Stapleton
Journal:  J Viral Hepat       Date:  2009-09-15       Impact factor: 3.728

7.  GB virus type C E2 protein inhibits human immunodeficiency virus type 1 assembly through interference with HIV-1 gag plasma membrane targeting.

Authors:  Christine L Timmons; Qiujia Shao; Chenliang Wang; Ling Liu; Huanliang Liu; Xinhong Dong; Bindong Liu
Journal:  J Infect Dis       Date:  2013-01-09       Impact factor: 5.226

8.  A novel genotype of GB virus C: its identification and predominance among injecting drug users in Yunnan, China.

Authors:  Yue Feng; Wenhua Zhao; Yuemei Feng; Jiejie Dai; Zheng Li; Xiaoyan Zhang; Li Liu; Jie Bai; Huatang Zhang; Ling Lu; Xueshan Xia
Journal:  PLoS One       Date:  2011-10-06       Impact factor: 3.240

9.  Prevalence of human pegivirus-1 and sequence variability of its E2 glycoprotein estimated from screening donors of fetal stem cell-containing material.

Authors:  Yakov Vitrenko; Iryna Kostenko; Kateryna Kulebyakina; Khrystyna Sorochynska
Journal:  Virol J       Date:  2017-08-31       Impact factor: 4.099

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.